24/7 Customer Service (800) 927-7671

Cronin makes case for 3D printing drug in New York today

by • April 26, 2016 • No Comments

Professor Lee Cronin can lead a conference in New York now a days that aims to show the pharmaceutical industry that 3D printing is the next it requires to embrace right now.

Cronin has an expansive vision of making drugs outside the traditional laboratory environment, that may save the drug production companies massive amounts of money in the long run. His forward-thinking vision of bargain-priced robotics, the chemical internet and 3D printing may revolutionise the industry, if it has the stomach to embrace alter.

Additive making has slowly won over a number of complex industries, which include the aviation industry. Plane makers tend to assume perfection, lives depend on the product after all. This level of social proof is slowly converting the masses, but the pharmaceutical industry has given the yett a lukewarm reception so far.

Lee-Cronin-and-his-chempu-022

Just one drug is 3D printed

Right now only the anti-seizure medication Spritam (levetiracetam), is commercially generated with a 3D printing device. Cronin is the Regius Chair of Chemistry at the University of Glasgow and he is convinced that the whole industry may simplify the production system, improve the purity of the chemical make-up and automatize
the whole making system.

He believes it’s a easy way to streamline the pharmaceutical industry and take drug production out of the traditional lab.

The yett is to use configurable robotics to control the assembly of the reactionware and and so co-ordinate the chemical reactions,” he said. “In this way, we can use quite easy robotic formats for the chemical synthesis.

Initial investment is putting companies off

The pharmaceutical industry at sizeable has argued against the widespread adoption of 3D printing for the reason of the first investment. It is true, printing devices capable of making worthwhile amounts of drugs may be a leading investment. But the price of entry is dropping all the time.

Printers are getting faster, that reduces the unit cost, the high end of the construction is improving at breakneck speed and there are massive savings to be made in terms of facilities and shipping costs.

The current donate chain calls for the make of massive amounts of the drug at a time, as companies already have production runs for every drug that is and so stockpiled. Cronin can argue that the whole philosophy requires to alter if the industry adopts 3D printing. This can work to its advantage as it can switch to only in time making and can not have to keep vast amounts of inventory.

It is a cost with a payoff

Cronin accepts that there is an first cost and, with 3D printing advancing at an amazing rate, the machines can require to be updated regularly. The savings, yet, may additional than compensate them for the first outlay as labs, shipping and inventory can just become a thing of the past.

The 42-year-old is a big name in the industry and a passionate advocate of 3D printing as a way of delivering drugs to the developing world. He believes it is the solution to the shortage of anti-malaria drugs and other medication in Africa. So it stands to reason that he genuinely believes that the system can reduce the price of drug production across the board.

He is in addition working towards inorganic biology, a living being made of inorganic matter, that regularly brings him into contact with the brightest minds in Physics, Chemical and Electrical Engineering and Biology. So when he makes a point with this veracity and so it’s at very least worth listening to what he has to say.

Cronin takes to the 3D Innovation Stage at Interphex at the Javits Centre at 10:30am. If you are in the area it may be well worth your time. If you are not, words of yett leaders of this stature tend to find their way round the world sooner pretty than later in any case.

In this video, Cronin shares his yetts regarding what he calls “printing your own medicine” (2012)

Related


Latest posts
test

by admin • March 5, 2017